Floatz logo

f16il2

Acute Myeloid Leukemia

Philogen S.p.A.unclassifiedPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

685 Active assets in the Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Gemtuzumab
M.D. Anderson Cancer Center
Phase 4A
AMSACRINE
University Hospital, Toulouse
Phase 4BBB
Posaconazole
AstraZeneca
Phase 4BBB
(+)-VINCRISTINE
Janssen Research & Development, LLC
Phase 3BBB
AKLAVINE
Chinese PLA General Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

f16il2 is also rated in:

metastatic melanomaDormant
CC
Indicative ·
42 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
42 / 100
View asset →
neoplasmDormant
C
Indicative ·
38 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →